{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06194448\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NEOLA","nct_id":"NCT06194448","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neola-nct06194448. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEOLA","arms":[{"description":"Patients will receive open-label osimertinib induction treatment for 8 weeks (± 1 week window to account for patient variability and CRT scheduling), followed by CRT treatment for 6 weeks (± 1 week) and then osimertinib maintenance treatment until RECIST 1.1-defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the patient requests to stop the study treatment.","label":"Open-Label Osimertinib Induction Treatment","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-07-07","type":"ESTIMATED"},"conditions":["Lung Cancer"],"enrollment":{"count":76,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["Tagrisso, AZD9291"],"type":"DRUG"},{"name":"Cisplatin or Carboplatin; Pemetrexed or Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Radiation","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"AstraZeneca","official_title":"A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS (Progression-Free Survival)","timeFrame":"Assessed from date of first dose to progression (up to a maximum of approximately 4 years)"}],"references":[{"citation":"Aredo JV, Peled N, Arriola E, Wakelee H, Ahn MJ, Kwint MH, Taylor R, van der Gronde T, Nasirova F, Chen M. Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol. Future Oncol. 2025 Dec;21(29):3731-3737. doi: 10.1080/14796694.2025.2587569. Epub 2025 Nov 14.","pmid":"41236484","type":"DERIVED"}],"start_date":{"date":"2024-04-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","url":"https://clinicaltrials.gov/study/NCT06194448"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neola-nct06194448"}